Allovir (ALVR)
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) the...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 9.810
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- Market Beat · Feb 12 at 10:36 AM
AlloVir (NASDAQ:ALVR) Shares Up 10.7% - Here's What Happened
- Acceswire · Jun 17, 2025 at 02:00 PM
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Investors to Connect
- StockTitan · Mar 18, 2025 at 08:21 PM
Kalaris Announces Closing of Merger with AlloVir | KLRS Stock News
- Tip Ranks · Mar 12, 2025 at 08:50 PM
AlloVir Stockholders Approve Key Amendment and Merger
- Unusual Whales · Mar 12, 2025 at 08:22 PM
Kalaris and AlloVir merger approved by stockholders; combined company to trade under "KLRS" on Nasdaq.
